Spotlight On December 2024's Leading Penny Stocks

As December 2024 unfolds, the U.S. stock market presents a mixed landscape, with the Dow Jones Industrial Average marking its fifth consecutive day of gains while the S&P 500 and Nasdaq Composite see minor declines. In this context, investors often turn to penny stocks—smaller or newer companies that can offer significant opportunities despite their somewhat outdated name. By focusing on those with strong financial foundations and potential for growth, investors can uncover hidden value in these lesser-known equities.

Top 10 Penny Stocks In The United States
Name Share Price Market Cap Financial Health Rating
Inter & Co (NasdaqGS:INTR) $4.39 $1.94B ★★★★☆☆
QuantaSing Group (NasdaqGM:QSG) $3.08 $120.12M ★★★★★★
BAB (OTCPK:BABB) $0.9075 $6.35M ★★★★★★
Imperial Petroleum (NasdaqCM:IMPP) $2.88 $87.05M ★★★★★★
ZTEST Electronics (OTCPK:ZTST.F) $0.2392 $8.46M ★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U) $4.50 $67.38M ★★★★★★
Smith Micro Software (NasdaqCM:SMSI) $0.9971 $15.52M ★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT) $0.859 $75.24M ★★★★★☆
Zynerba Pharmaceuticals (NasdaqCM:ZYNE) $1.30 $65.6M ★★★★★☆
Safe Bulkers (NYSE:SB) $3.57 $387.6M ★★★★☆☆

Click here to see the full list of 720 stocks from our US Penny Stocks screener.
Let's explore several standout options from the results in the screener.
Blade Air Mobility (NasdaqCM:BLDE)
Simply Wall St Financial Health Rating: ★★★★★☆☆
Overview: Blade Air Mobility, Inc. offers air transportation alternatives to alleviate congested ground routes in the United States and has a market cap of approximately $325.79 million.
Operations: The company's revenue is derived from two main segments: Medical, which generated $142.42 million, and Passenger services, contributing $99.39 million.
Market Cap: $325.79M
Blade Air Mobility, Inc. has been actively pursuing strategic growth through acquisitions, with $140 million earmarked for tactical investments in its medical segment. Despite a market cap of approximately $325.79 million and revenue from medical ($142.42 million) and passenger services ($99.39 million), the company remains unprofitable, with a net loss of $17.51 million for the first nine months of 2024. The management team is experienced, and the company is debt-free with sufficient cash runway for over three years based on current free cash flow levels, though shareholder dilution has occurred recently by 4.9%.
Jump into the full analysis health report here for a deeper understanding of Blade Air Mobility.
Examine Blade Air Mobility's earnings growth report to understand how analysts expect it to perform.
NasdaqCM:BLDE Financial Position Analysis as at Dec 2024
Gevo (NasdaqCM:GEVO)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Gevo, Inc. is a carbon abatement company with a market cap of $349.09 million.
Operations: The company generates revenue from two main segments: Gevo, which contributes $0.96 million, and Renewable Natural Gas, accounting for $14.63 million.
Market Cap: $349.09M
Gevo, Inc., with a market cap of US$349.09 million, operates in the renewable energy sector and is currently unprofitable. The company reported third-quarter sales of US$1.97 million, down from US$4.53 million the previous year, with a net loss widening to US$21.16 million. Gevo's financial health shows more cash than total debt and short-term assets exceeding liabilities, providing some stability despite ongoing losses. Recent developments include an extended partnership with LG Chem to commercialize its Ethanol-to-Olefins technology for sustainable products, signaling potential future revenue streams if successfully executed and scaled up in the bioplastic market.
Click here to discover the nuances of Gevo with our detailed analytical financial health report.
Learn about Gevo's future growth trajectory here.
NasdaqCM:GEVO Debt to Equity History and Analysis as at Dec 2024
Clover Health Investments (NasdaqGS:CLOV)
Simply Wall St Financial Health Rating: ★★★★★★☆
Overview: Clover Health Investments, Corp. offers Medicare Advantage plans in the United States and has a market cap of approximately $1.60 billion.
Operations: The company's revenue is derived entirely from the United States, totaling $2.12 billion.
Market Cap: $1.6B
Clover Health Investments, Corp., with a market cap of US$1.60 billion, remains unprofitable but has shown progress by significantly narrowing its net loss from US$41.47 million to US$9.16 million in the latest quarter compared to the previous year. The company is debt-free and maintains a stable cash runway exceeding three years based on current free cash flow levels. Despite shareholder dilution over the past year, Clover's short-term assets comfortably cover both short- and long-term liabilities. Recent initiatives include launching enhanced Medicare Advantage plans in New Jersey for 2025, aiming to offer competitive healthcare options amid rising costs for seniors.
Take a closer look at Clover Health Investments' potential here in our financial health report.
Evaluate Clover Health Investments' prospects by accessing our earnings growth report.
NasdaqGS:CLOV Debt to Equity History and Analysis as at Dec 2024
As the U.S. market anticipates the Federal Reserve's decision on interest rates, stock futures are pointing to a higher open, suggesting a potential rebound from recent downturns. For investors looking beyond large-cap stocks, penny stocks—often representing smaller or newer companies—remain an intriguing area of exploration despite their historical connotations. These stocks can offer hidden value when backed by strong financials and growth potential, and this article will highlight three such opportunities that could provide both stability and upside in today's market landscape.
Top 10 Penny Stocks In The United States
Name Share Price Market Cap Financial Health Rating
Inter & Co (NasdaqGS:INTR) $4.46 $1.94B ★★★★☆☆
QuantaSing Group (NasdaqGM:QSG) $3.08 $145.16M ★★★★★★
BAB (OTCPK:BABB) $0.9075 $6.35M ★★★★★★
Imperial Petroleum (NasdaqCM:IMPP) $2.99 $91.9M ★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U) $4.50 $69.71M ★★★★★★
ZTEST Electronics (OTCPK:ZTST.F) $0.2392 $8.46M ★★★★★★
RLX Technology (NYSE:RLX) $1.88 $2.51B ★★★★★★
Zynerba Pharmaceuticals (NasdaqCM:ZYNE) $1.30 $65.6M ★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT) $0.859 $75.24M ★★★★★☆
Safe Bulkers (NYSE:SB) $3.81 $401.48M ★★★★☆☆

Click here to see the full list of 720 stocks from our US Penny Stocks screener.
Let's explore several standout options from the results in the screener.
Lixte Biotechnology Holdings (NasdaqCM:LIXT)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company dedicated to identifying targets for cancer drug development and commercializing cancer therapies, with a market cap of $4.72 million.
Operations: Lixte Biotechnology Holdings, Inc. does not currently report any revenue segments.
Market Cap: $4.72M
Lixte Biotechnology Holdings, with a market cap of US$4.72 million, is currently pre-revenue and unprofitable, facing challenges typical for penny stocks in the biotech sector. The company has less than a year of cash runway and no long-term liabilities, but its